| Entry |
|
|---|
| Name |
Pindolol (JP18/USP/INN);
Blocklin-L (TN);
Carvisken (TN);
Visken (TN) |
|---|
| Product |
|
|---|
| Generic |
PINDOLOL (ANI Pharmaceuticals), PINDOLOL (Bayshore Pharmaceuticals LLC), PINDOLOL (Marlex Pharmaceuticals), PINDOLOL (Mylan Pharmaceuticals), PINDOLOL (Nostrum Laboratories), PINDOLOL (PD-Rx Pharmaceuticals), PINDOLOL (PD-Rx Pharmaceuticals), PINDOLOL (PD-Rx Pharmaceuticals), PINDOLOL (Sun Pharmaceutical Industries), PINDOLOL (Zydus Lifesciences Limited), PINDOLOL (Zydus Pharmaceuticals USA) |
|---|
| Formula |
C14H20N2O2
|
|---|
| Exact mass |
248.1525
|
|---|
| Mol weight |
248.32
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Cardiovascular agent
DG01466 Adrenergic receptor antagonist
DG01464 beta-Adrenergic receptor antagonist (Beta blocker)
DG01653 Antiarrhythmics
DG01806 Class II antiarrhythmic agent
DG03231 Antihypertensive
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
Transporter substrate
DG02854 SLC22A2 substrate
|
|---|
| Remark |
|
|---|
| Efficacy |
Antiarrhythmic, Antihypertensive, Vasodilator, beta-Adrenergic receptor antagonist |
|---|
| Disease |
|
|---|
| Comment |
Propranolol derivative
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
| hsa04261 | Adrenergic signaling in cardiomyocytes |
|
|---|
| Metabolism |
Enzyme: CYP2D6 [HSA: 1565]
Transporter: SLC22A2 [HSA: 6582]
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07214 | beta-Adrenergic receptor agonists/antagonists |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
C CARDIOVASCULAR SYSTEM
C07 BETA BLOCKING AGENTS
C07A BETA BLOCKING AGENTS
C07AA Beta blocking agents, non-selective
C07AA03 Pindolol
D00513 Pindolol (JP18/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Cardiovascular Agents
Beta-adrenergic Blocking Agents
Beta-adrenergic Blocking Agents, Other
Pindolol
D00513 Pindolol (JP18/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
21 Cardiovascular agents
212 Antiarrhythmic agents
2123 Beta blockers
D00513 Pindolol (JP18/USP/INN)
214 Antihypertensives
2149 Others
D00513 Pindolol (JP18/USP/INN)
Drug groups [BR:br08330]
Cardiovascular agent
DG01466 Adrenergic receptor antagonist
DG01464 beta-Adrenergic receptor antagonist (Beta blocker)
D00513 Pindolol
DG01653 Antiarrhythmics
DG01806 Class II antiarrhythmic agent
D00513 Pindolol
DG03231 Antihypertensive
D00513 Pindolol
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
D00513 Pindolol
Transporter substrate
DG02854 SLC22A2 substrate
D00513 Pindolol
Drug classes [BR:br08332]
Cardiovascular agent
DG03231 Antihypertensive
D00513 Pindolol
DG01653 Antiarrhythmics
D00513 Pindolol
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Adrenaline
ADRB
D00513 Pindolol (JP18/USP/INN) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D00513 Pindolol
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D00513
Drug transporters
D00513
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 18
1 C8y C 18.9000 -17.2200
2 C8y C 18.9000 -18.6200
3 C8y C 20.1600 -16.5200
4 C8x C 17.5700 -16.8000
5 N4x N 17.5700 -19.1100
6 C8x C 20.1600 -19.3200
7 C8x C 21.3500 -17.2200
8 O2a O 20.1600 -15.1200
9 C8x C 16.8000 -17.9200
10 C8x C 21.3500 -18.6200
11 C1b C 21.3500 -14.4200
12 C1c C 22.5400 -15.1200
13 C1b C 23.8000 -14.4200
14 O1a O 22.5400 -16.5200
15 N1b N 24.9900 -15.1200
16 C1c C 26.1800 -14.4200
17 C1a C 27.4400 -15.1200
18 C1a C 26.1800 -13.0200
BOND 19
1 1 2 2
2 1 3 1
3 1 4 1
4 2 5 1
5 2 6 1
6 3 7 2
7 3 8 1
8 4 9 2
9 6 10 2
10 8 11 1
11 11 12 1
12 12 13 1
13 12 14 1
14 13 15 1
15 15 16 1
16 16 17 1
17 16 18 1
18 5 9 1
19 7 10 1
|
|---|
